AB0474 REAL-WORLD SINGLE CENTER USE OF UPADACITINIB IN RHEUMATOID ARTHRITIS PATIENTS, INCLUDING THOSE REFRACTORY TO FIRST-GENERATION JAK INHIBITORS

Abstract

BackgroundIn practice, bDMARDs and subsequent first-generation JAK inhibitors (JAKi) have significantly improved the management of rheumatoid arthritis (RA), but there are still patients refractory or intolerant to multiple b/tsDMARDs. The...